Löwenberg, Bob × Pabst, Thomas Vellenga, Edo van Putten, Wim Schouten, Harry C Graux, Carlos Ferrant, Augustin Sonneveld, Pieter Biemond, Bart J Gratwohl, Alois de Greef, Georgine E Verdonck, Leo F Schaafsma, Martijn R Gregor, Michael Theobald, Matthias Schanz, Urs Maertens, Johan Ossenkoppele, Gert J Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group #
New England Journal of Medicine vol:364 issue:11 pages:1027-1036
Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated.